|Back to main|
CR Bard Inc. (BCR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
CR Bard's adjusted earnings rose 18.6% to $1.91 per share for the 2014-first quarter and beat the Zacks Consensus Estimate by $0.05 as well as its own guidance. Revenues grew 8.0% and comfortably outpaced the mark. On the back of better results, the company retained its bottom line guidance for 2014. It has also raised its dividend and expanded share repurchase program recently. Potential benefits from the Gore litigation are now expected in 2014. However, we remain concerned about the stringent sales environment in the U.S. Moreover, some of Bard's businesses are experiencing significant pricing and competitive pressures and low-single digit growth in international markets. As a result, we reiterate our Neutral recommendation on CR Bard and set a target of $153.00.
Headquartered in Murray Hill, N.J., C. R. Bard Inc. (BCR) is engaged in the design, manufacture, packaging, distribution, and marketing of medical, surgical, diagnostic, and patient care devices worldwide. The company became publicly traded in 1963 and has approximately 12,200 employees. CR Bard serves hospitals, physicians, and clinics in the U.S., Europe, and Japan.
CR Bard's products are sold to hospitals, individual health care professionals, extended care facilities, and alternate site facilities using a combination of direct sales and distributors. The company has a mix of competitors ranging from large manufacturers with multiple business lines like Boston Scientific Corp. (BSX) and Johnson & Johnson (JNJ) to smaller manufacturers that offer a limited selection of products like Angiodynamics Inc. (ANGO).
CR Bard offers its products around the concept of disease state management under four major product groups: Vascular, Urology, Oncology, and Surgical Specialty products.
Vascular (27.4% of total revenue in the 2014-first quarter): Through its Vascular division, the company develops and markets a vast range of products for the peripheral vascular market. Its minimally invasive vascular products include peripheral angioplasty stents, catheters, guidewires, introducers, Vena Cava filters, biopsy devices, electrophysiology products and implantable vascular grafts.
Urology (25.2%): The company's Urology offerings include basic drainage products (including urinary tract infection catheters), continence products (including surgical sling products) and urological specialty products.
Oncology (27.4%): Oncology products cover a wide range of devices, which include specialty access catheters such as peripherally inserted central catheters or PICC, ports and biopsy devices. These are used in the treatment and management of multiple cancers and other diseases and disorders.
Surgical Specialties (16.9%): These products include mesh for vessel and hernia repair, irrigation devices for orthopedic, laparoscopic and gynecological procedures and products for topical hemostasis. With the acquisition of Neomend, the business included new products in its portfolio viz. surgical sealants and anti-adhesive products used during surgical procedures. The remaining 3.1% of revenues is generated from the Other Product group.
CR Bard Inc. (BCR): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BARD C R INC (BCR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research